Dr. Reddy's Laboratories Ltd. has officially announced a board meeting scheduled for May 12, 2026, to consider the audited standalone and consolidated financial results for the fourth quarter and full financial year ending March 31, 2026. The pharmaceutical company communicated this development through formal notifications to stock exchanges on March 23, 2026.

Board Meeting Announcement

The meeting of the Board of Directors will specifically focus on reviewing and approving the audited financial results for Q4FY26 and FY26. This announcement has been made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring compliance with regulatory requirements for material information disclosure.

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, Dr. Reddy's Laboratories has announced the closure of its trading window for company securities. The restriction will be effective from March 25, 2026, to May 14, 2026, both days inclusive.

Exchange Notifications

The company has formally notified multiple stock exchanges where its securities are listed, including the National Stock Exchange of India Ltd. (Scrip Code: DRREDDY), BSE Limited (Scrip Code: 500124), New York Stock Exchange Inc. (Stock Code: RDY), and NSE IFSC Ltd. (Stock Code: DRREDDY). The notification was digitally signed by K Randhir Singh, Company Secretary, Compliance Officer & Head-CSR.

Corporate Governance Compliance

This announcement reflects Dr. Reddy's Laboratories' commitment to maintaining transparent corporate governance practices and regulatory compliance. The trading window closure is a standard requirement designed to prevent insider trading during periods when material financial information is being finalized and before its public disclosure across all trading platforms where the company's securities are available.

Dr. Reddy's Laboratories has officially announced the launch of Obeda®, India's first DCGI-approved generic semaglutide injection for Type 2 diabetes management. This milestone positions the company as the first Indian pharmaceutical firm to receive Drugs Controller General of India approval for generic semaglutide, marking its Day-1 entry into the GLP-1 receptor agonists therapy space.

Clinical Efficacy and Safety Profile

The launch follows successful completion of a comprehensive Phase III clinical study that enrolled 312 participants. The head-to-head comparison demonstrated Obeda®'s non-inferior efficacy and safety profile comparable to the innovator drug.

Product Specifications and Pricing

Obeda® semaglutide injection comes in a user-friendly format designed for patient convenience and adherence. The product addresses India's significant diabetes burden, with over 101 million adults living with the condition according to the ICMR-INDIAB study.

In-house Development Capabilities

Dr. Reddy's developed both API and formulation entirely in-house, demonstrating its strength in complex product development and peptide science. This approach reflects the company's decade-long expertise in peptide technology and commitment to bringing GLP-1 therapies to market.

Erez Israeli, Chief Executive Officer of Dr. Reddy's, emphasized the significance: "Today's launch marks a significant step in our commitment to expand our portfolio in critical therapeutic areas with differentiated solutions to patients in India and across global markets. Our foray into GLP-1 therapies reflects our capabilities in complex product development and peptide science."

Patient Support and Market Strategy

The company has developed SemaKare™, a comprehensive patient support system enhanced by a digital app. This platform provides onboarding guidance and field device-counsellor assistance, injection training and tele-support services, therapy-adherence monitoring, and treatment outcome improvement initiatives.

Dr. Reddy's plans to establish metabolic centres of excellence across India, serving as integrated hubs for advancing diabetes and metabolic disorders treatment. These centres will focus on healthcare professional education, evidence-based management, and real-world evidence generation.

Global Expansion Plans

As part of its phase-1 launch strategy, Dr. Reddy's aims to introduce generic semaglutide in several countries, subject to regulatory approval. The company's "One Product, One Quality" approach ensures consistent high-quality standards across all markets.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), stated: "As the first generic semaglutide approved in the country, today's announcement reflects our science-led approach and our long-standing efforts in expanding access to advanced therapies in India."